JUNIPER BIOLOGICS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa 2024-06-24 09:00
Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards 2024-04-22 09:00
Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards 2024-04-22 09:00
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider 2024-03-25 09:51
Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023 2024-01-08 09:00
Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore 2023-12-22 07:00
Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards 2023-10-24 12:00
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA 2023-01-12 13:02
JUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONAL 2022-12-23 09:35
Juniper Biologics Establishes Global Headquarters in Singapore 2022-09-15 09:53
Juniper Biologics Pte. Ltd. signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East* 2022-09-01 17:00
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* 2022-05-04 14:00
JUNIPER BIOLOGICS ACQUIRES CELL-MEDIATED GENE THERAPY TG-C LD FOR TREATMENT OF KNEE OSTEOARTHRITIS 2022-04-13 07:57
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive 2021-04-15 16:30
1